semaglutide if not diabetic for weight loss in non-diabetics Novo Nordisk's Ozempic® pill, the

By activating GLP-1 receptors in the brain, Semaglutide helps reduce appetite and promote feelings of fullness, leading to decreased food intake and, ultimately, weight loss

Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)

Semaglutide also causes nausea and appetite suppression as part of its mechanism, especially at higher doses or during dose escalation phases

TRIUMPH Phase 3 program listings (NCT05929066, NCT05931367, NCT06383390)

It must be refrigerated immediately

There has been significant research in recent years focused on the other potential benefits of GLP-1 analogues, many of which could be due to the impact they have on body mass index (BMI) and obesity